Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent (nitrogen mustard) presented as an oral formulation for systemic use. It is employed in the treatment of chronic lymphocytic leukemia, Hodgkin's lymphoma, and other lymphoid malignancies, primarily in adult patients.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, oncology centres, pharmacies and clinics worldwide across multiple regulatory markets.

Leukeran (chlorambucil) is used in hematologic cancers where DNA alkylation is required to control malignant cell proliferation.

Chronic lymphocytic leukemia (CLL): reduces leukemic cell count and prolongs survival. Hodgkin's lymphoma: induces remission by targeting proliferating lymphoid cells. Other lymphoid malignancies: provides disease control in selected non‑Hodgkin lymphomas and related disorders.

Chlorambucil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Diarrhea - Fatigue or weakness - Mild bone‑marrow suppression (e.g., transient leukopenia)

Serious or Rare Side Effects: - Severe myelosuppression (profound neutropenia, anemia, thrombocytopenia) - Secondary malignancies (e.g., acute leukemia) - Severe gastrointestinal ulceration or hemorrhage - Pulmonary toxicity (interstitial pneumonitis)

When prescribing or handling Leukeran, several precautions should be observed to minimize risks. - Monitor blood counts: perform regular complete blood count (CBC) assessments to detect myelosuppression. - Assess liver and kidney function: adjust therapy if hepatic or renal impairment is present. - Avoid use in patients with active infections: postpone treatment until infection resolves. - Counsel on contraception: advise women of childbearing potential to use effective contraception during therapy and for a defined period after cessation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Chlorambucil can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: may cause additive bone‑marrow suppression. - Strong CYP2D6 inhibitors (e.g., fluoxetine): can increase chlorambucil plasma levels. - Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): enhanced bleeding risk due to mucosal toxicity. - Allopurinol: may increase risk of myelosuppression. - NSAIDs: can exacerbate gastrointestinal irritation and ulceration.